Navigation Links
High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer

Among a group of mostly older male veterans suffering from chronic obstructive pulmonary disease (COPD), an illness that offers a greater// susceptibility to lung cancer, researchers found that regular use of high dose inhaled corticosteroids (ICS) lowered the risk of developing lung cancer.

David H. Au, M.D., M.S., of the Veterans Administration Puget Sound Health Care System in Seattle, along with five associates found that among 10,474 patients with COPD, 517 were considered regular users of ICS.

Among users of more than 1,200 micrograms of ICS per day, the relative risk for lung cancer was lowered to 0.39. For users of less than 1,200 micrograms per day, the relative risk was 1.13. (A relative risk of 1 means there is no difference in risk between two groups.)

Over the next four years, the researchers found that among a total of 9,957 nonusers of ICS, 402 developed lung cancer. For 298 users of ICS at a level below 1,200 micrograms per day, 16 developed lung cancer. Among 219 patients who used over 1,200 micrograms per day, five developed lung cancer.

“Lung cancer is the most common cause of cancer-related death in the United States and accounts for more deaths each year than breast, prostate and colon-rectal cancer combined,” said Dr. Au. “Studies such as the Lung Health Study have demonstrated that the most common cause of death among subjects with COPD is lung cancer.”

In 2004, more than 11 million U.S. adults were estimated to suffer from COPD, which results from chronic bronchitis and emphysema, two inflammatory lung diseases that frequently co-exist and interfere with normal breathing. Smoking is the primary cause of COPD.

“Tobacco smoke is a well-recognized stimulant of systemic and local inflammation and the role of inflammation in the causal pathway for both lung cancer and COPD has been suggested,” said Dr. Au.

The researchers noted that ICS have been shown in prospectiv e studies to suppress systemic markers of inflammation such as C-reactive protein and to reduce airway inflammation.

They hypothesized that higher doses of ICS among the male veterans reduced such factors as local airway inflammation, cell turnover, and the propagation of genetic errors. Consequently, these effects could lead to a subsequent reduction in lung cancer risk.

In an editorial on the research in the same issue of the journal, York E. Miller, M.D., of the Denver Veterans Affairs Medical Center, and Robert L. Keith, M.D., of the University of Colorado Cancer Center, Denver, wrote:

“Although the data at present are certainly not definitive, inhaled corticosteroids deserve further consideration for lung cancer chemoprevention. Adequately powered, prospective, controlled trials with prolonged follow-up to capture effects on a carcinogenic process that progresses over years will ultimately be needed to determine efficacy. If these could be designed to capture outcomes of interest relevant to both lung cancer and COPD, joint funding by the National Cancer Institute and the National Heart Lung Blood Institute would then be desirable.”

“The risk reduction suggested by the studies discussed would be a clinically significant achievement, particularly in light of the continued lung cancer epidemic,” the editorialists continued. “Many additional agents are undergoing evaluation for lung cancer chemoprevention, including micronutrients, tyrosine kinase inhibitors, and blockers or agonists of signaling pathways as reviewed. It is hoped, within the next decade, that chemoprevention of lung cancer in high-risk individuals (beyond smoking cessation) will be standard in pulmonary and primary care settings as is influenza vaccination or cardiac risk factor modification. The potential for benefit is just as great.”

Source-Newswie
SRM/L
'"/>




Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor ... event brings together top non-profit leaders, ultimate organizations, and coaches from around the US. ... Bay Area Disc Program Director of Youth and Education, describes this year YUCC as ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... , February 5, 2016 ... market research report "Fetal (Labor & Delivery) and Neonatal ... Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, ... MarketsandMarkets, This report studies the global market over the ... estimated at USD 6.28 Billion in 2015 and is ...
(Date:2/4/2016)... Feb. 4, 2016 For hospitals considering enrollment ... already participating in the program, the Health Resources and ... as the , Mega-Guidance , could have significant impact ... published in September 2016. Essential Insights , ... Marketing , summarizes the Mega-Guidance,s key proposed changes, including ...
Breaking Medicine Technology: